Clinical Trial Update: Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 clinical trial is evaluating UTAA91 Injection for relapsed/refractory autoimmune diseases. The study is not yet recruiting and includes systemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies
• Rheumatoid Arthritis
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• UTAA91

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis | EARLY_Phase 1 | Status: NOT_YET_RECRUITING